Traws Pharma, Inc.
Price Action
Technical Summary
CONSOLIDATINGTraws Pharma, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 38), showing significant lag compared to the market leaders. Earnings growth of 98% provides fundamental context to the price action. Investors should exercise caution due to high volatility (122% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.39 | +22.66% | ABOVE |
| 50 SMA | $1.65 | +2.89% | ABOVE |
| 100 SMA | $1.71 | -0.67% | BELOW |
| 150 SMA | $1.95 | -12.84% | BELOW |
| 200 SMA | $1.88 | -9.49% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TRAW in an uptrend right now?
TRAW has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is TRAW overbought or oversold?
TRAW's RSI (14) is 60. The stock is in neutral territory, neither overbought nor oversold.
Is TRAW outperforming the market?
TRAW has a Relative Strength (RS) Rating of 38 out of 99. TRAW is currently lagging the broader market.
Where is TRAW in its 52-week range?
TRAW is trading at $1.70, which is 52% of its 52-week high ($3.27) and 32% above its 52-week low ($0.97).
How volatile is TRAW?
TRAW has a Beta of 1.60 and 52-week volatility of 122%. It's more volatile than the S&P 500 - expect bigger swings.